Bioprocess Automation Market Report 2026

The bioprocess automation market size has grown rapidly in recent years. It will grow from $6.4 billion in 2025 to $7.21 billion in 2026 at a compound annual growth rate (CAGR) of 12.6%. The growth in the historic period can be attributed to growth of biopharmaceutical manufacturing, increasing complexity of biologics production, adoption of programmable control systems, demand for consistent product quality, expansion of clinical manufacturing operations.

The bioprocess automation market size is expected to see rapid growth in the next few years. It will grow to $11.52 billion in 2030 at a compound annual growth rate (CAGR) of 12.4%. The growth in the forecast period can be attributed to increasing investments in continuous bioprocessing, rising demand for scalable automation platforms, growth of cell and gene therapy manufacturing, integration of AI-driven process optimization, expansion of smart biomanufacturing facilities. Major trends in the forecast period include increasing adoption of automated bioprocess control platforms, rising integration of real-time process analytics, growing use of single-use bioprocessing automation, expansion of closed-loop process control systems, enhanced focus on data integrity and compliance.

The rising prevalence of personalized medicines is expected to drive growth in the bioprocess automation market in the coming years. Personalized medicine tailors healthcare decisions, treatments, and interventions to the unique characteristics of individual patients. Bioprocess automation supports this approach by enabling precise, scalable production of patient-specific therapies. For example, in February 2024, the Personalised Medicine Coalition, a US-based healthcare organization, reported that the FDA approved 16 new personalized treatments for rare disease patients in 2023, up from six approvals in 2022. As a result, the growing number of personalized medicines is fueling demand for bioprocess automation solutions.

Leading companies in the bioprocess automation market are developing innovative technologies, such as bioreactors, to streamline bioprocessing operations. A bioreactor is an engineered system that provides a controlled environment for biological and chemical reactions. For instance, in April 2023, Cytiva, a US-based technology company supporting therapeutic development and manufacturing, launched X-platform bioreactors to simplify single-use upstream bioprocessing. Offered initially in 50 and 200 L capacities, these bioreactors are easy to operate, flexible, and improve process efficiency through ergonomic enhancements, increased production capability, and simplified supply chain operations. They can be used to manufacture cell and gene therapies, viral vectors, and monoclonal antibodies (mAbs).

In September 2025, Thermo Fisher Scientific, a US-based life sciences and biopharma supplies leader, acquired the purification and filtration business of Solventum for an undisclosed amount. This acquisition enables Thermo Fisher to strengthen its bioprocess automation portfolio by expanding downstream processing capabilities, offering more comprehensive solutions for biologics, cell therapies, and drug manufacturing. Solventum’s purification and filtration business provides critical filtration technologies across multiple geographies.

Major companies operating in the bioprocess automation market are Thermo Fisher Scientific Inc., Danaher Corporation, Merck KGaA, Parker-Hannifin Corporation, Rockwell Automation Inc., Agilent Technologies Inc., Lonza Group AG, Waters Corporation, Getinge AB, Eppendorf SE, Repligen Corporation, BIONET Engineering, Pierre Guerin Technologies, Bioengineering AG, Genedata AG, ILS Automation LLC, INFORS HT AG, Synthace Ltd., Automated Control Concepts Inc., BlueSens gas sensor GmbH, Securecell AG, Flownamics Analytical Instruments Inc., PendoTECH LLC, Sartorius Stedim Biotech S.A.

North America was the largest region in the bioprocess automation market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the bioprocess automation market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the bioprocess automation market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The bioprocess automation market includes revenues earned by entities by providing services such as process automation, instrumentation and control systems, training and support services, and maintenance and upgrades. The market value includes the value of related goods sold by the service provider or included within the service offering. The bioprocess automation market also includes sales of bioreactors, fermenters, laboratory information management systems (LIMS), and integrated bioprocess platforms. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.